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Salicylate effect on platelets and
vascular thrombosis in rheumatoid arthritis
G i l b e r t B. B l u h m , M D , * Jeanne M . Riddle, P h D , * *
D o n a l d G . Pica, M D and G o r d o n D. Langejans, M D * * *

with a serum urate level above 5 mg% (7 of
12 vs 9 of 28). Neither "low" nor "antiinflammatory" levels of serum salicylate appear to afford protection from abnormal
PSA.
The authors consecutively reviewed 100
patients with classical RA diagnosed and
followed at Henry Ford Hospital (72 females
and 28 males) to determine their incidence
of thrombotic episodes. The mean age of the
group was 59 years and the mean duration of
follow-up was 14 years. They found 43
clotting episodes in 30 patients (21 females).
There were 14 myocardial infarctions (5 in
females); 19 episodes of
thrombophlebitis
(12 in females); 4 pulmonary
embolisms
(females); 5 cerebral vascular accidents (4 in
females); and one female with peripheral
arterial occlusive disease. No significant
correlation with rheumatoid nodules, stage
of disease progression or functional class of
disease was noted when those patients with
thromboembolic complications were compared to the others who manifested no clinical thrombosis. This study suggests that in
vivo salicylate fails to inhibit PSA as determined by EM and by retrospective review of
100 patients who used prolonged daily dosage of salicylate. The thrombotic episodes
were as frequent as in general population
surveys, except for data from a cerebral
vascular (stroke) survey.

Platelet surface activation was surveyed
by electron microscopy (EM) in 40 patients
with classical rheumatoid arthritis (fiA) without clinical evidence of recent intravascular
coagulation. Increased platelet surface activity (PSA) was noted in 8 of 25 females and
8 of 15 males (16 of 40 or 40%). Abnormal
PSA failed to correlate with either the presence of rheumatoid nodules or the titer of
rheumatoid
factor. Hyperactive
platelet
populations, however, did tend to correlate
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none at all. Also, some patients were selected because they exhibited subcutaneous
rheumatoid nodules.

C L I N I C A L investigation has documented
the ability of acetylsalicylic acid (ASA) to
influence hemostasis. ASA prolongs the
bleeding time in normal individuals'' while
other studies indicate that platelet aggregation can be inhibited by both ASA and
sodium salicylate.^' ^ Platelet release activity
is diminished by ASA in man."*' ^ Because
aspirin has antithrombotic potential, studies
are underway to assess its benefit in the
prevention of vascular thrombosis.

When the specimen for evaluation by
electron microscopy was obtained, blood
was also taken from the same venipuncture
for the following determinations: uric acid,
salicylate, blood urea nitrogen, rheumatoid
factor titer, complete blood count and platelet count per mm.^
For the retrospective review, patients with
classical RA were chosen consecutively
from a group diagnosed at Henry Ford Hospital (HFH) during the years of 1950-1955.
Their selection was based upon prolonged
care at Henry Ford Hospital so that a reliable
assessment could be made of any other
health problems which had occurred since
the onset of their rheumatoid arthritis, particularly vascular complications. The details
of each medical record were reviewed and
data pertinent to the study were tabulated
from 100 patients. The regular use of salicylate by these patients was d o c u m e n t e d
especially.

Accepting the role of the platelet in thrombosis we asked the question, "can the daily
use of ASA beneficially influence the patency of blood vessels?" The long term use
and consequent benefit of ASA was suggested when the drug's effect on platelets
from patients using from 0.6 to 5.3 grams of
aspirin daily for three weeks to two years
were contrasted with the platelet data of a
control group who had not taken ASA for at
least three weeks. Serotonin release from
platelets was abolished and secondary aggregation did not occur with epinephrine in
those patients using aspirin.*
The purpose of this paper is to report the
state of platelet activation as determined by
electron microscopy (EM) in 40 patients with
classical rheumatoid arthritis (RA) who exhibited no clinical evidence of recent intravascular c o a g u l a t i o n ; and to report the
prevalence of thrombotic episodes in 100
patients with classical RA diagnosed and
followed at Henry Ford Hospital.

Results
Platelets: Total platelet counts were performed on each of the 40 patients surveyed
and ranged from 160,000 to 457,500/mm.^
Only two of the platelet counts were under
200,000 and six exceeded 400,000. The
blood urea nitrogen was within the normal
range (normal up to 25 mg%) with one
exception, and it was increased to 30 mg%.

Patient selection

Differential counts by EM: We determined
surface activation by employing a technique
described in detail elsewhere.' The method
can be described briefly as follows: A sample of whole blood is drawn using nonwettable equipment. The blood specimen is
introduced immediately into a vessel cont a i n i n g a m i c r o s c o p e slide coated w i t h
Formvarand an appropriate amountof 3.8%
sodium citrate to prevent clotting. The specimen is incubated at 37°C for exactly eight

Each patient chosen for a platelet evaluation had classical RA, was ambulatory and
participating in a gold injection program, did
not require any other a n t i - i n f l a m m a t o r y
agent except ASA, and gave no history or
clinical evidence for recent intravascular
thrombosis. Some patients were deliberately
selected who were taking regular daily doses
of ASA varying between 2.6 to 4.2 grams,
while others were using a smaller dosage or
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Figure 1
Round disc shaped platelets and a predominance of dendritic forms, the vast majority of which comprise a
normal differential count as determined by electron microscopy. X 9200

Figure 2
Abnormal platelet surface activation is noted by the increased numbers of spread forms and / or
aggregates which are illustrated above. X 5700
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minutes during which time the platelets
adhere to the surface of the Formvar. The
slide with adherent platelets is removed,
washed in Tyrode's solution, fixed in buffered osmium and washed in distilled water.
Copper grids are then placed on the Formvar
surface of the glass slide where the platelets
have adhered. Scotch tape is used to strip the
copper grids and Formvar film with its adhering platelets from the slide. The specimens
are then ready for study by transmission EM.

inhibit PSA,^ we compared platelet morphology with the titers of RF Rheumatoid
factor titer was determined bythe sensitized
sheep red blood cell agglutination test after
the test serum was absorbed overnight with
sheep red blood cells. A titer of 80 or less is
negative. In a group of patients with RA, 70%
should have a positive titer and our selected
group of patients matched well since a positive titer was present in 29 of the 40 (72%).
Abnormal PSA was found in 5 of 11 RF
negative patients (45%) and in 11 of 29 RF
positive patients (38%). Overall, the level of
the RF titer did not appear to influence
platelet reactivity (Figure 3). However, there
is a trend, which is not significant (Chi
square 1.67; P~0.2), that the female patients
who have no nodules but demonstrate a
positive RF titer may be afforded some protection by RF (2/11 vs 4 / 9 ) . The number of
male patients was too few to evaluate in this
manner (Figure 3).

The platelet morphology (PM) for normal
individuals consists of a few round, discshaped platelets and a predominance of
dendritic type platelets (Figure 1). Duringthe
identification and recording of 100 single
platelets, an average of 68 ± 50 small
platelet aggregates are seen normally. Abnormal platelet surface activation is demonstrated by the occurrence of an increased
number of spread form platelets (Figure 2) at
a percentage greater than 19 and/or platelet
aggregates numbering more than 119. These
values are consistent in our experience regardless of age or sex.

Rheumatoid nodules occur in 30% of the
patients with RA. Our group of 40 had 16
patients w i t h nodules (40%). The pathophysiology of a nodule in RA is known to
be related to local vessel t h r o m b o s i s .
Rheumatoid nodules are usually associated
with a positive RF titer and this finding was
also true in our group. Therefore, we decided to relate the presence of abnormal PSA
in our patients to the occurrence of subcutaneous nodules. Platelet populations
from nine patients of 24 (37%) without
nodules were activated and six patients of 16
(37%) with nodules; thus, no apparent influence was suggested by the vascular occlusion known to exist in rheumatoid nodules
(Figure 4).

Increased platelet surface activation (PSA)
was noted in 16 of 40 patients (40%). We
found abnormal PSA in 8 of 25 females and 8
of 15 males. There were four patients who
manifested abnormal PSA which was expressed by an elevated percent of spread
platelet forms alone. Two other patients
exhibited an increased number of small
platelet aggregates, but a normal number of
spread platelets. However, both parameters
were increased in the other 10 patients who
showed abnormal PSA. Indeed, this has
been our experience also in an evaluation of
95 patients with primary gout where 49
(51%)were found to have abnormal PSA and
the majority of these exhibited both increased numbers of spread forms and
aggregates.^

Platelet morphology (PM)and Serum uric
acid (SUA): We have previously published
data which support the concept that the
occurrence of abnormal PM in primary gout
may be related to a serum uric acid value
greater than 5-6 mg%.^ This study provided
us with an opportunity to study the influence
of "non-gouty" uric acid levels on PSA. The
uricase method was used for uric acid analysis with a range of normal from 1-7 mg%.

Platelet morphology (PM), Rheumatoid
factor (RF) and Rheumatoid nodules: Because RF is a macroglobulin and large molecular molecules have been shown to
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There were five patients with a SUA of 5
mg% and three showed a hyperactive platelet population. Using the remaining 35 patients, 6 of 23 patients (26%) with a SUA less
than 5 mg% and 7 of 12 patients (58%) with
SUAgreaterthan 5 mg% exhibited an abnormal PSA. There is a trend for a serum uric
level of greater than 5 mg% to be associated
with hyperactive platelet populations (Chi
square 3.51; P > .05, but < .1) (Figure 5).

classical RA diagnosed and f o l l o w e d at
Henry Ford Hospital (HFH) to determine
their prevalence of c l i n i c a l t h r o m b o s i s .
There were 72 females and 28 males. The
mean age of the group was 59 years. All but
three of the patients were in the fifth through
the eighth decades. The average duration of
rheumatoid disease was 17 years and the
mean duration of patient observation was 14
years (Figure 7).

Platelet morphology (PM) and Serum salicylate levels (SS): The determination of SS
has an inherent error of 3 mg%. Some of the
patients chosen gave a history of ASA intolerance or denied the recent need of ASA for
several weeks. These 10 patients showed SS
levels below 3 mg%. Interestingly four of
these patients (40%) had platelets exhibiting
abnormal PSA, the same relative percentage
as d e m o n s t r a t e d f o r t h e t o t a l g r o u p
surveyed.

Nine of 28 males and 21 of 78 females
experienced clotting episodes. The males
were more prone to Mis and females experienced more frequent thrombophlebitis (Figure 8). The tendency for males to be at a
greater risk for arterial thrombosis in our
group is not an unexpected finding when
one reviews the m o r t a l i t y rates for cardiovascular disease.''^
Forty-three thrombotic episodes occurred
in 30 patients, of which 21 were women. In
14 myocardialinfarctions, five female patients were afflicted. Cerebral vascular accidents totaled five, and four of these were
female patients. The most common clotting
episode was due to thrombophlebitis and
these numbered 19; 12 occured in women.
Pulmonary e m b o l i s m d e v e l o p e d in four
female patients. One woman exhibited peripheral arterial occlusive disease. The average duration of rheumatoid disease before
clinical thrombosis occurred was 16 years.
No significant correlation with rheumatoid
nodules, stage of disease progression, or
functional class was evident when patients
with and without thrombosis were compared. Four of the patients who had myocardial infarctions had either diabetes mellitus
or hypertension as an identifiable risk factor
(Figure 9).

Pharmacological studies on oral ingestion
of ASA have shown that two tablets (325 mg
each) generally gives a peakSS level in three
hours of between 5-10 mg% and by six hours
after ingestion the SS is reduced to an insignificant level." In the range of 5-10 mg%,
platelet populations from five of 11 patients
exhibited abnormal PSA (45%). Therapeutic
anti-inflammatory SS levels are maintained
between 15-30 mg% and platelets from five
of 11 patients (45%) in that range showed
abnormal PM. Considering all patients with
a SS level of over 10 mg%, the platelets
showed increased surface a c t i v a t i o n in
seven of 19 (37%). In this parameter of our
study PSA did not seem to be inhibited by
either " l o w " or "anti-inflammatory" levels
of SS (Figure 6).

Certainly one cannot make valid statistical
comparisons between epidemiological surveys which include large numbers of individuals and the limited Henry Ford Hospital
survey of patients with RA. Nevertheless, a
trend is appreciated when comparison is
made with other available data. There are
conflicting data in findings from one of our

Survey of RA patients and thrombosis
Is there a trend for protection from thrombotic episodes in a group of patients who use
ASA daily and regularly either as an analgesic or anti-inflammatory agent? In an att e m p t to a n s w e r t h i s q u e s t i o n , w e
consecutively reviewed 100 patients with
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they had a higher incidence of Ml than the
groups used for comparison. While our sample of female patients is small, the data fail to
suggest that ASA offers protection against Ml
in these RA patients.

previous reported surveys of 280 patients
with primary gout," the Framingham'''' and
the Tecumseh''^ studies that included the
occurrence of coronary heart disease and
the report on the prevalence of "completed
strokes" reported by Halsey et al in 1968.'^

The report of Halsey et aP^ on a prospective study of strokes in an epidemiology
survey noted 95 complete strokes (excluded
transient ischemic attacks) in 1,802 individuals (47% were males). Of these 891
occurred in patients aged 60-69 years of
which 68 experienced complete strokes
(7.6%). Two of 48 patients in our RA group
(age 60-69) experienced a stroke (4.1%),
which is about half the rate found by Halsey
et al.'"'

Based on our HFH surveys, a protection is
only suggested for the patient with RA on
aspirin in the seventh decade. In the primary
gout patients all but three were males and
they had a total mean follow-up period of
1,400 patient years; 244 were in the fifth
through the eighth decades." Although the
RA patients numbered 100 and only 28 were
males, the mean observation period was also
1,400 patients years. Since both groups were
surveyed for the same thrombotic episodes,
the results are compared. In the sixth and
seventh decades there was a sufficient number of patients in both groups to analyze. In
the seventh decade (60-69 years) 7 of 48
patients (15) experienced thrombosis while
they were taking ASA; whereas 23 thrombotic episodes occurred in 66 gout patients
(35%). The reverse situation was true for the
sixth decade (50-59 years) (Table I).
However, calculations showed a statistically
significant difference between the groups
only for the seventh decade (Chi square
9.42; P < .01, but > .001).

Discussion
Although high hopes are held for aspirin
as an effective agent for clinical use in
reducing the tendency for thrombosis, it
does seem unusualthatclinical observations
have never reported or suggested a decreased risk for thrombosis associated with
ASA ingestion. In fact, a recent controlled
study of aspirin effect on postoperative venous thrombosis showed no advantage over
the placebo-treated group," while another
clinical study which evaluated the ability of
aspirin to prevent venous thrombosis and
pulmonary embolism after hip surgery suggested an equal benefit for aspirin with those
patients receiving warfarin, but a better benefit than dipyridamole." The pharmacological doses required to influence platelet
release activity and secondary aggregation
in in vitro experiments are 2 to 40 times the
therapeutic level of salicylate which one can
practically obtain by the ingestion of aspirin.^-" Decreased hearing and tinnitus occur at 25 to 30 mg%; at 35 to 40 mg%
hyperpnea begins as a manifestation of salicylate intoxication and acidosis."

By sorting out the data from the Framingham and Tecumseh studies for the incidence of coronary heart disease (CHD) for
females, males and by decades, we could
compare the prevalence of Ml in the female
patients with RA. The Framingham data does
not extend beyond 62 years. None of our
female patients experienced an Ml before
the sixth decade. In the sixth decade our
Henry Ford Hospital RA group experienced
about twice the prevalence of M l as the
Framingham or Tecumseh group even
though the latter studies included either Ml
or angina pectoris as evidence of coronary
heart disease. The prevalence in the seventh
and eighth decades was comparable with
the Tecumseh survey (Figure 10). Although
the male patients with RA are not charted.

A report of the in vivo effect of ASA on
platelets measured by serotonin release and
platelet aggregation experiments w h e n
"long term ingestion" has been used sug-
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Table I

THROMBOSIS IN TWO ARTHRITIC
HFH

GROUPS

Decade

Fifth

Sixth

Seventh

Eighth

Total

63

9d

66

21

244

8

27

23

4

62

13%

29%

35%

19%

25%

10

22

48

17

97

5

9

7

3

24

50%

41%

15%

18%

GOUTY PATIENTS:
Number
Thrombosed

RHEUMATOID PATIENTS:
Number
Thrombosed

25%

NOTE: Each arthritic group represents about 1400 patient years observation
for Ml, CVA, PVOD, TP, PE.
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One cannot make valid statistical comparisons between the limited Henry Ford
Hospital survey and the population surveys
available as to prevalence of thrombotic
episodes because of the great disparity in
numbers of i n d i v i d u a l s in each group.
However, there is conflicting evidence of
ASA protection from clinical thrombotic episodes in rheumatoid arthritic patients. Because primary hyperuricemia is known to
correlate well with abnormal PSA and gout
patients have an increased incidence of
vascular occlusive disease, it may be an
injustice to compare our RA patients with
our gout patients. If that be so, we should not
conclude a benefit for ASA in the RA group
for the seventh decade.

gested the promise of decreasing thrombosis.^ Our efforts to relate serum salicylate
levels to the degreeof platelet surface activation during "long term ingestion" of ASA has
yielded less promising data. By the EM evaluation of platelet morphology there were no
trends of surface inhibition by " l o w " or
"anti-inflammatory" serum levels of salicylate. The correlation of serum uric acid values
above 5 mg% with an abnormal PSA and
aggregation suggests a possible harmful
effect of ASA (Chi square 3.51; P >.02, but
<.1). Low dose salicylate ingestion (less than
two grams per day) is known to decrease
tubular secretion of uric acid and cause a rise
in serum urate. This rise in serum uric acid
could actually indirectly serve to increase
platelet responsiveness in some individuals.

It seems unlikely to us from our data that
" a couple of aspirin a day will keep thrombosis away!" However, it is possible that
factors exist in the chronically ill patient with
RA that override any protection from thrombosis that may be afforded to a " n o r m a l "
individual regularly ingesting aspirin. Obviously, our study c a n n o t answer that
possibility.

A rheumatoid nodule develops in association with arteriole and venous occlusion.
Where the vessels are patent, the nodular
tissue t e r m i n a t e s . T h e occurrence of nodules in RA offers a type of vascular thrombosis for evaluation. Also, rheumatoid factor
titers are positive regularly in rheumatoid
patients w i t h nodules. In o n g o i n g intravascular clotting abnormal PSA has been
demonstrated and has been shown to persist
for as long as 18 months.''^ If rheumatoid
nodules portend an intravascular thrombotic episode, it was not reflected in the platelet
differential counts of our RA patients nor by
the number of clotting episodes in the retrospective review of the Henry Ford Hospital
patients with rheumatoid arthritis. The presence of rheumatoid factor, a macroglobulin,
in significantly positive titers did not appear
to inhibit the PSA. Unfortunately insufficient
numbers of male patients exclude assessment of a trend for them.
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